At the news
? BEARISHIMPACT 7/10 8-K filed Apr 21, 2026 at 16:18 ET
Rigel Pharmaceuticals announced that Eli Lilly has elected to terminate their 2021 License and Collaboration Agreement, effective June 15, 2026. The agreement covered the development and commercialization of ocadusertib and other RIPK1 inhibitors. Rigel will regain full rights but does not expect future milestones or royalties.
- Eli Lilly terminated the License and Collaboration Agreement dated February 18, 2021
- Termination becomes effective on June 15, 2026
- Agreement covered ocadusertib (R552) and other RIPK1 inhibitors for CNS and non-CNS diseases
- Rigel will regain full rights to the licensed compounds
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access